

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

BLUEBIRD BIO, INC.,
Petitioner

v.

SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH,
Patent Owner

Patent No. 8,058,061

DECLARATION OF JÖRG BUNGERT, Ph.D.

Table of Contents

	Page
I. Introduction—U.S. Patent No. 8,058,061	1
II. Qualifications.....	2
III. Summary of Opinions.....	4
IV. Person of Ordinary Skill in the Art.....	6
V. Technological Overview.....	7
A. Inherited Hemoglobin Disorders and Gene Therapies.....	9
B. A Predicate to Gene Therapy: Understanding the Regulation of Hemoglobin Genes	12
C. Development of Vectors for Gene Therapy	17
VI. Overview of the '061 Patent.....	21
VII. Claim Construction.....	25
VIII. The Priority Date for the '061 Patent	25
IX. Overview of the Prior Art.....	31
A. Chad M. May, “Therapeutic Hemoglobin Synthesis in Beta-Thalassemic Mice Expressing Lentivirus-Encoded Human Beta-Globin,” Cornell University (2001) (“ <i>May Thesis</i> ”) (Ex. 1004).....	31
B. Chad May, <i>et al.</i> , “Therapeutic Haemoglobin Synthesis in β -Thalassaemic Mice Expressing Lentivirus-Encoded Human β -Globin,” Nature, 406(6791) (2000) (“ <i>May Article</i> ”) (Ex. 1005)	32
C. May <i>et al.</i> , “Lentiviral-Mediated Transfer of the Human β -Globin Gene and Large Locus Control Region Elements Permit Sustained Production of Therapeutic Levels of β -Globin in Long-Term Bone Marrow Chimeras,” Mol. Therapy, 1(5) (2000), (“ <i>May Abstract</i> ”) (Ex. 1006).....	35
D. Himanen, <i>et al.</i> , “A Recombinant Sickle Hemoglobin Triple Mutant With Independent Inhibitory Effects on Polymerization,” J. Biol. Chem., 271(41):25152-56 (1996) (Ex. 1047).....	36

X.	Ground 1: The <i>May Thesis</i> Teaches	
	All of the Limitations of Claims 1, 2, 6-7, and 11 of the '061 Patent.....	38
A.	Claim 1	38
1.	[1.pre] “An isolated mammalian hematopoietic progenitor cell or an isolated mammalian stem cell comprising”	38
2.	[1.a] “a recombinant lentiviral vector which comprises,”	39
3.	[1.b] “a nucleic acid encoding a functional globin operably linked to a 3.2-kb nucleotide fragment which consists essentially of three contiguous nucleotide fragments obtainable from a human β -globin locus control region (LCR),”	39
4.	[1.c] “the three fragments being a <i>BstXI</i> and <i>SnaBI</i> , HS2-spanning nucleotide fragment of said LCR, a <i>BamHI</i> and <i>HindIII</i> , HS3-spanning nucleotide fragment of said LCR, and a <i>BamHI</i> and <i>BanII</i> , HS4-spanning nucleotide fragment of said LCR,”	41
5.	[1.d] “said vector providing expression of the globin in a mammal <i>in vivo</i> .”	42
B.	Claim 2: “The cell of claim 1, wherein the mammalian hematopoietic progenitor cell or the stem cell is a human cell.”	43
C.	Claim 6: “The cell of claim 1, wherein said functional globin is a wild-type globin.”	43
D.	Claim 7: “The cells of claim 1, wherein said functional globin is a β -globin.”	44
E.	Claim 11	44
1.	[11.pre] “A method for making a mammalian hematopoietic progenitor cell or a mammalian stem cell composition which comprises”	44
2.	[11.a] “(a) preparing a recombinant lentiviral vector comprising a nucleic acid encoding a functional globin operably linked to a 3.2-kb nucleotide fragment which consists essentially of three contiguous nucleotide fragments obtainable from a human β -globin locus control region (LCR),”	45

3.	[11.b] “the three fragments being a <i>BstXI</i> and <i>SnaBI</i> , HS2-spanning nucleotide fragment of said LCR, a <i>BamHI</i> and <i>HindIII</i> , HS3-spanning nucleotide fragment of said LCR, and a <i>BamHI</i> and <i>BanII</i> , HS4-spanning nucleotide fragment of said LCR,”	46
4.	[11.c] “said vector providing expression of the globin in a mammal <i>in vivo</i> ; and”	47
5.	[11.d] “(b) obtaining hematopoietic progenitor cells or stem cells from the mammalian individual,”	47
6.	[11.e] “and transducing the cells with the recombinant vector.”	48
XI.	Ground 2: The <i>May Thesis</i> in Combination With <i>Himanen</i> Teaches or Suggests All of the Limitations of Claim 5 of the '061 Patent	49
A.	Claim 5: “The cell of claim 1, wherein said functional globin is a mutant globin.”	49
XII.	Ground 3: The <i>May Article</i> Teaches All of the Limitations of Claims 1, 2, 6-7, and 11 of the '061 Patent	51
A.	Claim 1	51
1.	[1.pre] “An isolated mammalian hematopoietic progenitor cell or an isolated mammalian stem cell comprising”	51
2.	[1.a] “a recombinant lentiviral vector which comprises,”	52
3.	[1.b] “a nucleic acid encoding a functional globin operably linked to a 3.2-kb nucleotide fragment which consists essentially of three contiguous nucleotide fragments obtainable from a human β -globin locus control region (LCR),”	53
4.	[1.c] “the three fragments being a <i>BstXI</i> and <i>SnaBI</i> , HS2-spanning nucleotide fragment of said LCR, a <i>BamHI</i> and <i>HindIII</i> , HS3-spanning nucleotide fragment of said LCR, and a <i>BamHI</i> and <i>BanII</i> , HS4-spanning nucleotide fragment of said LCR,”	55
5.	[1.d] “said vector providing expression of the globin in a mammal <i>in vivo</i> .”	63

B.	Claim 2: “The cell of claim 1, wherein the mammalian hematopoietic progenitor cell or the stem cell is a human cell.”	64
C.	Claim 6: “The cell of claim 1, wherein said functional globin is a wild-type globin.”	65
D.	Claim 7: “The cells of claim 1, wherein said functional globin is a β -globin.”	66
E.	Claim 11	66
1.	[11.pre] “A method for making a mammalian hematopoietic progenitor cell or a mammalian stem cell composition which comprises”	66
2.	[11.a] “(a) preparing a recombinant lentiviral vector comprising a nucleic acid encoding a functional globin operably linked to a 3.2-kb nucleotide fragment which consists essentially of three contiguous nucleotide fragments obtainable from a human β -globin locus control region (LCR),”	67
3.	[11.b] “the three fragments being a <i>BstXI</i> and <i>SnaBI</i> , HS2-spanning nucleotide fragment of said LCR, a <i>BamHI</i> and <i>HindIII</i> , HS3-spanning nucleotide fragment of said LCR, and a <i>BamHI</i> and <i>BanII</i> , HS4-spanning nucleotide fragment of said LCR,”	68
4.	[11.c] “said vector providing expression of the globin in a mammal <i>in vivo</i> ; and”	69
5.	[11.d] “(b) obtaining hematopoietic progenitor cells or stem cells from the mammalian individual,”	69
6.	[11.e] “and transducing the cells with the recombinant vector.”	70
XIII.	Ground 4: The <i>May Article</i> Teaches or Suggests All of the Limitations of Claims 1, 2, 6, 7, and 11 of the '061 Patent.....	70
XIV.	Ground 5: The <i>May Article</i> in Combination with <i>Himanen</i> Teaches or Suggests All of the Limitations of Claim 5 of the '061 Patent.....	73
A.	Claim 5: “The cell of claim 1, wherein said functional globin is a mutant globin.”	74

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.